Certificate of Competence in Lymphoma - sixth cohort (CCL6)

The Certificate of Competence in Lymphoma (CCL), launched in 2013, is the first competence programme to focus on the improvement of both the clinical and the scientific capability of oncologists, ensuring better-quality management of lymphoma patients.

• Duration: 15 months
• Structure: 6 online modules & 3 in presence seminars: participation in LyFE 2023, ICML 2023, and 4-day-CCL stand-alone seminar 2024
• Collaborating university: University of Ulm, Germany
• Chairs: James Armitage (US), Franco Cavalli (CH), Manuela Hoechstetter (D), Andrew Lister (UK), Stephan Stilgenbauer (D), Emanuele Zucca (CH)
• Start date: January 2023
• Application status: Closed. The next edition of CCL will take place in 2025/2026

Upon successful completion of the programme and after passing the final exam, participants will obtain an academic certificate issued by the European School of Oncology and the University of Ulm.

For further information please contact: Sarah Ortelli, sortelli@eso.net

LINK TO THE PLATFORM HERE.

Admission

Admission to the Certificate of Competence in Lymphoma (CCL) programme will be by competitive application only and the selection will be based on the eligibility criteria and on the selection procedure.

Applications will be considered if received completed with all required documents and within the deadline. Attendance is limited to 25 participants.

Decisions on admissions are made by the appointed Programme Chair.

Attendance

To obtain the Certificate of Competence in Lymphoma (CCL) programme, it will be compulsory that participants will attend all seminars and modules according to the provided timeline.

Insurance

The organisers bear no responsibility for untoward events in relation to the participation in the seminars. Participants are advised to take out their own personal and travel insurance coverage.

Eligibility

The programme is designed for oncologists and haematologists (medical oncology, haematology, internal medicine, radiation oncology, pathology), but it is equally accessible to graduates in natural sciences, who are engaged in the field of oncology, especially in the field of lymphoma.

• Medical doctors:

• Master degree from an accredited college or university (e.g. state examination in medicine) in medicine or an equivalent degree at the level of state examination in medicine and have had at least two years residency training in a relevant institution.
• Natural scientists:
  
  
• Master degree from an accredited college or university in a course of studies in natural sciences or an equivalent degree at the level of at least three years of studies or in a course of studies with essentially the same contents at an accredited college or university and at least two years of professional experience in oncology.
  
  
• The following additional achievements will increase the assessment rate of the application:
  
  
• Further professional experience related to the course of studies
• Completion of an additional qualification in oncology (specialist training as a physician or international equivalent)
• Publications, as evidenced by cumulative impact factors greater than 10
• At least one year of relevant oncological experience in a foreign country

In keeping with the ESO mission, the cost of the CCL programme is generously subsidized by the European School of Oncology (ESO).

The tuition fee which remains to be paid by each participant is EUR 5.400.

In a further effort to make the cost of this programme accessible to professionals living in emerging economies, a discounted fee of EUR 3.000 will be applied to residents of lower and middle income countries as defined by The World Bank.

The tuition fee includes:

• Access to the in-person seminars foreseen by the programme, including registration for the indicated congresses and accommodation: LyFE 2023 (Bellinzona, Switzerland), ICML 2023 (Lugano, Switzerland), 4-day CCL stand-alone seminar 2024 (Ulm Germany)
• Access to the online modules via a dedicated online platform
• Access to all exams required by the programme

The tuition fee does not include:

• Travel to the in-person seminars

REFUNDS

Cancellation of participation in the programme should be submitted in writing. A refund of the tuition fee will be considered if the programme has not started yet and on a case-by-case basis.

Chairs

• James O. Armitage, University of Nebraska Medical Center, Omaha, US
• Manuela Hoechstetter, Munich Clinic Schwabing, Academic Teaching Hospital Ludwig-Maximilian University (LMU), DE
• Franco Cavalli, Foundation for the Institute of Oncology Research, Bellinzona, CH
• Andrew Lister, St. Bartholomew's Hospital, London, UK
• Stephan Stilgenbauer, Ulm University Hospital, Ulm, DE
• Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, CH

Scientific Directors

• Ranjana Advani, Stanford Cancer Institute, Stanford, US
• Elias Campo, University of Barcelona, Barcelona, ES
• Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Novara, IT
• Mary Gospodarowicz, Princess Margaret Hospital - University of Toronto, Toronto, CA
• Georg Hopfinger, Medical University of Vienna, Vienna, AT
• Julie M. Vose, University of Nebraska Medical Center, Omaha, US

Conceptual Development and Organisation

• Uta Schmidt-Strassburger, Ulm, DE
• Sarah Ortelli, ESO, Bellinzona, CH